TGFB1 and neoplasm: This does not necessarily imply that anti-GARP:TGF-β1 mAbs will have no anti-tumor activity as monotherapy in patients with cancer, but it does suggest that they are able to overcome primary or acquired resistance to PD-1/PD-L1 blockade.